Teva Pharmaceutical Industries Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Humanigen Announces Agreement With French CDMO For Fill And Finish Services For Lenzilumab Humanigen,

https://www.investing.com/news/stock-market-news/teva-pharm-q4-profit-rises-sees-more-growth-in-key-drugs-2760316

Teva Pharmaceutical (TEVA) is trading ~1% lower on Wednesday in the pre-market after posting a mixed performance with its Q4 2021 financials

Teva Pharmaceutical Industries Ltd. (TEVA) CEO Kåre Schultz on Q4 2021 Results - Earnings Call Transcript

Shares of Teva Pharmaceutical Industries Ltd. shed 1.2% in premarket trading Wednesday, after the Israel-based generic drug maker reported fourth-quarter profit that topped expectations but revenue that missed, as COVID-19 continued to impact patient behavior and prescribing patterns. Teva swung to a net loss of $159 million, or 14 cents a share, from net income of $150 million, or 14 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share of 77 cents topped the FactSet consensus of 73 cents. Revenue fell 7.9% to $4.10 billion, but missed the FactSet consensus of $4.28 billion, as generic product revenue in North America and Copaxone offset higher revenue from Austedo and Ajovy. For 2022, Teva expects adjusted EPS of $2.40 to $2.60, below the FactSet consensus of $2.67, and revenue of $15.6 billion to $16.2 billion, compared with expectations of $16.1 billion. The stock has dropped 10.9% over the past three months through Tuesday, while the S&P 500 has declined 3.5%.

Teva Pharmaceutical press release (TEVA): Q4 Non-GAAP EPS of $0.77 beats by $0.04.Revenue of $4.1B (-8.9% Y/Y) misses by $180M.2022 business outlook: Revenues are expected to be $15.6…

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2021. Q4 2021 and FY 2021 highlights: Q4 2021 FY 2021 Revenues $4.1 billion $15.9 billion GAAP diluted EPS $(0.14) $0.38 Non-GAAP diluted EPS $0.77 $2.58 Cash flow generated from operating activities $456 million $798 million Free cash flow $716 million $2,196 million 2022 business outlook: Revenues are expected to be $

Teva Pharmaceutical Industries Ltd's  TEVA Q4 sales reached $4.1 billion, shrinking 8% Y/Y, missing the consensus of $4.29 billion.  Get the Inside Access Traders Are Using to Profit More and Win B

Teva Pharmaceutical Industries beat fourth-quarter profit expectations as gains in North American sales of Huntington's disease treatment Austedo and migraine product Ajovy offset declines in generics

Shares of Teva Pharmaceutical Industries Ltd. TEVA, -2.01% shed 1.2% in premarket trading Wednesday, after the Israel-based generic drug maker reported fourth-quarter profit that topped expectations b

Teva Pharmaceutical (NYSE:TEVA) is scheduled to announce Q4 earnings results on Wednesday, February 9th, before market open.The consensus EPS Estimate is $0.73 (+7.4% Y/Y) and the

Teva Pharmaceutical Industries Ltd (NYSE: TEVA ) has reached a settlement worth $225 million to resolve claims the Company fueled an opioid epidemic in Texas. Texas Attorney General Ken Paxton said Teva agreed to pay $150 million over 15 years … Full story available on Benzinga.com

Teva Pharmaceutical Industries Ltd was facing claims that they fueled an opioid epidemic in Texas by improperly marketing addictive pain medications.

Texas Attorney General Ken Paxton announced an opioid settlement worth $225M with Teva Pharmaceutical <> on Monday.Per the terms, Teva (TEVA) will also provide $75M of…

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and its affiliates, has reached an agreement with the Attorney General (AG) of Texas that settles the state''s and its subdivisions opioid-related claims. Under the terms of the settlement, Teva will pay Texas $150 million over a 15-year time period and will provide the recently launched, lifesaving medicine generic Narcan ® (naloxone hydrochloride nasal spray), valued at $75 million (wholesale acquisition cost) over 10 years. "Expanding access to lifesaving medicines is at the core of Teva''s mission. The Texas Attorney General is taking steps to address the opioid epidemic in the State by negotiating a settlement that includes critical medicines as part of their solution," said Kåre Schultz, Teva''s President and CEO. "While the settlement includes no admission of wrongdoing by Teva or its affiliates, it remains in the best interest of Teva to put these cases behind us and continue to focus on the patients we serve every day." Naloxone is a life-saving medication that can reverse an overdose from opioids. 1 As of December 2021, Teva has made available the first generic version of this critical medicine and has included this product in the Company''s ongoing pursuit of a national or narrower settlement with individual states such as the deal announced today.